Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H23NO.BrH |
Molecular Weight | 338.283 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.[H][C@@]12CC3=C(C=C(O)C=C3)[C@]4(CCCC[C@@]14[H])CCN2C
InChI
InChIKey=WVFGKGPFQSEWON-DYWKTHLTSA-N
InChI=1S/C17H23NO.BrH/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17;/h5-6,11,14,16,19H,2-4,7-10H2,1H3;1H/t14-,16+,17+;/m0./s1
Molecular Formula | C17H23NO |
Molecular Weight | 257.3706 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | BrH |
Molecular Weight | 80.912 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/13097351
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13097351
Racemorphan is racemic mixture of an antitussive and dissociative hallucinogen Dextrorphan and an opioid analgesic Levorphanol. Racemorphan itself is under international control per the Single Convention on Narcotic Drugs 1961 and is therefore listed as a Schedule II Narcotic controlled substance.
CNS Activity
Sources: https://www.drugs.com/pro/levo-dromoran.html
Curator's Comment: http://dx.doi.org/10.3109/10717549309022764
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26635068 |
2.3 nM [Ki] | ||
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26635068 |
0.13 nM [Ki] | ||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26635068 |
4.2 nM [Ki] | ||
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14742749 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
236 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10211869/ |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PROFENAMINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2685 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10211869/ |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PROFENAMINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10211869/ |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PROFENAMINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10211869/ |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PROFENAMINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
5 mg multiple, subcutaneous Dose: 5 mg Route: subcutaneous Route: multiple Dose: 5 mg Sources: |
unhealthy, 54 years n = 1 Health Status: unhealthy Age Group: 54 years Sex: F Population Size: 1 Sources: |
Other AEs: Respiratory rate decreased, Respiratory rhythm disorder... Other AEs: Respiratory rate decreased Sources: Respiratory rhythm disorder Corneal reflex decreased Fixed dilated pupils |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Corneal reflex decreased | 5 mg multiple, subcutaneous Dose: 5 mg Route: subcutaneous Route: multiple Dose: 5 mg Sources: |
unhealthy, 54 years n = 1 Health Status: unhealthy Age Group: 54 years Sex: F Population Size: 1 Sources: |
|
Fixed dilated pupils | 5 mg multiple, subcutaneous Dose: 5 mg Route: subcutaneous Route: multiple Dose: 5 mg Sources: |
unhealthy, 54 years n = 1 Health Status: unhealthy Age Group: 54 years Sex: F Population Size: 1 Sources: |
|
Respiratory rate decreased | 5 mg multiple, subcutaneous Dose: 5 mg Route: subcutaneous Route: multiple Dose: 5 mg Sources: |
unhealthy, 54 years n = 1 Health Status: unhealthy Age Group: 54 years Sex: F Population Size: 1 Sources: |
|
Respiratory rhythm disorder | 5 mg multiple, subcutaneous Dose: 5 mg Route: subcutaneous Route: multiple Dose: 5 mg Sources: |
unhealthy, 54 years n = 1 Health Status: unhealthy Age Group: 54 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Comparison of opioid agonists in maintaining responding and in suppressing morphine withdrawal in rhesus monkeys. | 1981 |
|
Prostaglandin hyperalgesia, V: a peripheral analgesic receptor for opiates. | 1982 Jan |
|
Relative cataleptic potency of narcotic analgesics, including 3,6-dibutanoylmorphine and 6-monoacetylmorphine. | 1984 |
|
Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist. | 1991 Mar-Apr |
|
Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. | 1995 Sep |
|
Central discriminative effects of morphine in rats: training via intracerebroventricular administration. | 2001 Dec |
|
The safety of dextromethorphan in pregnancy : results of a controlled study. | 2001 Feb |
|
Interface for coupling nonaqueous wide-bore capillary electrophoresis with mass spectrometry. | 2002 Feb |
|
Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cyclase superactivation is independent of agonist-induced phosphorylation, desensitization, internalization, and down-regulation. | 2003 Dec |
|
Opioids and chronic neuropathic pain. | 2003 Mar 27 |
|
Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor. | 2003 May |
|
Can levorphanol be used like methadone for intractable refractory pain? | 2007 Apr |
|
Does purity of supplements count? | 2007 Jan |
|
The effect of opiates on the activity of human placental aromatase/CYP19. | 2007 Jan 15 |
|
Levorphanol: the forgotten opioid. | 2007 Mar |
|
High-affinity carbamate analogues of morphinan at opioid receptors. | 2007 Mar 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/levo-dromoran.html
The usual recommended starting dose of Levorphanol for oral administration is 2 mg.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:29:00 GMT 2023
by
admin
on
Sat Dec 16 17:29:00 GMT 2023
|
Record UNII |
5URK043N48
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5URK043N48
Created by
admin on Sat Dec 16 17:29:00 GMT 2023 , Edited by admin on Sat Dec 16 17:29:00 GMT 2023
|
PRIMARY | |||
|
5464026
Created by
admin on Sat Dec 16 17:29:00 GMT 2023 , Edited by admin on Sat Dec 16 17:29:00 GMT 2023
|
PRIMARY | |||
|
5985-35-3
Created by
admin on Sat Dec 16 17:29:00 GMT 2023 , Edited by admin on Sat Dec 16 17:29:00 GMT 2023
|
PRIMARY | |||
|
m6794
Created by
admin on Sat Dec 16 17:29:00 GMT 2023 , Edited by admin on Sat Dec 16 17:29:00 GMT 2023
|
PRIMARY | Merck Index | ||
|
117861
Created by
admin on Sat Dec 16 17:29:00 GMT 2023 , Edited by admin on Sat Dec 16 17:29:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |